

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 DEC 01 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances enhanced
NEWS 4 APR 07 STN is raising the limits on saved answers
NEWS 5 APR 24 CA/Cplus now has more comprehensive patent assignee information
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7 APR 28 CAS patent authority coverage expanded
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9 APR 28 Limits doubled for structure searching in CAS REGISTRY
NEWS 10 MAY 08 STN Express, Version 8.4, now available
NEWS 11 MAY 11 STN on the Web enhanced
NEWS 12 MAY 11 BEILSTEIN substance information now available on STN Easy
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 17 JUN 25 NUTRACEUT and PHARMAML discontinued

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:17:20 ON 25 JUN 2009

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
TOTAL
SESSION
0.22
0.22
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:17:36 ON 25 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2009 HIGHEST RN 1159631-40-9
DICTIONARY FILE UPDATES: 23 JUN 2009 HIGHEST RN 1159631-40-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\1520078 updated 2.str



chain nodes :
7 8 9 16 17 18 21 22 23 24 25 27 28

```

ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
3-28 6-7 7-8 7-16 8-9 9-10 12-17 13-21 14-18 21-22 22-23 23-24 23-25
24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
3-28 7-16 12-17 13-21 14-18 21-22 22-23 23-24 23-25 24-27
exact bonds :
6-7 7-8 8-9 9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

```

G1:X,Ak,O,S

G2:O,S

G3:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS


```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 X,Ak,O,S

G2 O,S

G3 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss ful
FULL SEARCH INITIATED 15:17:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 27933 TO ITERATE

100.0% PROCESSED 27933 ITERATIONS
SEARCH TIME: 00.00.01

157 ANSWERS

L2 157 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
185.88 186.10

FILE 'CAPLUS' ENTERED AT 15:18:06 ON 25 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jun 2009 VOL 150 ISS 26
FILE LAST UPDATED: 24 Jun 2009 (20090624/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12
L3 8 L2



=> d 13 1-8 ibib abs hitstr

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1470011 CAPLUS
DOCUMENT NUMBER: 148:100385
TITLE: Preparation of 1,3-diphenylpropane derivatives,
particularly 2-[4-(3-oxo-3-phenylpropyl)phenoxy]-2-
methylpropanoic acids and related derivatives, as PPAR
agonists for treating diseases especially dyslipidemia
INVENTOR(S): Delhomel, Jean-Francois; Hanf, Remy; Caumont-Bertrand,
Karine
PATENT ASSIGNEE(S): Genfit, Fr.
SOURCE: PCT Int. Appl., 108pp.

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007147879	A1	20071227	WO 2007-EP56224	20070621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2902789	A1	20071228	FR 2006-5540	20060621
AU 2007262938	A1	20071227	AU 2007-262938	20070621
CA 2655643	A1	20071227	CA 2007-2655643	20070621
EP 2046715	A1	20090415	EP 2007-730296	20070621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
IN 2009MN00149	A	20090515	IN 2009-MN149	20090119
KR 2009035535	A	20090409	KR 2009-701319	20090121
PRIORITY APPLN. INFO.:			FR 2006-5540	A 20060621
			WO 2007-EP56224	W 20070621

OTHER SOURCE(S): MARPAT 148:100385
 GI



AB Title compds. I [X1 = R1, G1R1; X2 = halo, R2, G2R2; X3 = R3, G3R3; X4 = halo, R4, G4R4; X5 = R5, G5R5; R1 = H, nonhalogenated alkyl; R2 = H, alkyl; R3-R5 = independently H, (un)substituted alkyl; G1-G5 = independently O, S; with at least one of X3-X5 = R3, G3R3, R4, G4R4, R5, G5R5 in which G3-G5 = defined as above and R3-R5 = independently alkyl substituted with 1-2 substituents selected from CO2H and derivs., CONH2 and derivs., SO3H, SO2NH2 and derivs.; A = CR6R7, CO, C:N-OH, C:N-OR8; R6, R7 = independently H, OH, OR8, alkyl; R8 = independently alkyl substituted

with an aryl or cycloalkyl group; D = CH₂, CHY; Y = O- or S-heterocycle; with the exclusion of compds. I in which A = CH₂ and at least 3 of X₁-X₅ = H; and their stereoisomers, racemates, geometrical isomers, tautomers, salts, hydrates, solvates, solid forms and their mixts.] were prepared as PPAR activators, especially agonists, for treating dyslipidemia, diabetes type II and related diseases. Thus, reduction of 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid with triethylsilane in TFA at room temperature gave acid

II

(m.p. = 109-110°). Selected I were hPPAR α , hPPAR γ , and/or hPPAR δ activators in an induced luciferase activity via hPPAR α /Gal4, hPPAR γ /Gal4, and hPPAR δ /Gal4 transactivation assay. I displayed hypolipemic properties by lowering the plasmatic cholesterol and triglycerides rates. I are useful for treating diabetes type II, dyslipidemia, pathologies associated with metabolic syndrome, cardiovascular diseases, etc.

IT

824932-88-9 1000334-92-8 1000334-94-0

1000334-96-2 1000335-03-4

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 1,3-diphenylpropane derivs. as PPAR activators for treating diseases especially dyslipidemia)

RN

824932-88-9 CAPLUS

CN

Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN

1000334-92-8 CAPLUS

CN

Propanoic acid, 2-[4-[3-(4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN


1000334-94-0 CAPLUS

CN


Acetic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]- (CA INDEX NAME)



RN 1000334-96-2 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(4-propoxypyhenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 1000335-03-4 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:1470010 CAPLUS
 DOCUMENT NUMBER: 148:100384
 TITLE: Preparation of 1,3-diphenylpropane derivatives, particularly 2-[4-(3-oxo-3-phenylpropyl)phenoxy]-2-methylpropanoic acids and related derivatives, as PPAR agonists for treating diseases especially dyslipidemia
 Delhomel, Jean-Francois; Hanf, Remy; Caumont-Bertrand, Karine
 INVENTOR(S):
 PATENT ASSIGNEE(S): Genfit, Fr.
 SOURCE: PCT Int. Appl., 97pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2007147880	A1	20071227	WO 2007-EP56225	20070621			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HD, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	W: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	W: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS	FR 2902789	A1	20071228	FR 2006-5540	20060621
AU 2007262939	A1	20071227	AU 2007-262939	20070621			
CA 2655744	A1	20071227	CA 2007-2655744	20070621			
EP 2046716	A1	20090415	EP 2007-786798	20070621			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS	IN 2008BDN10605	A	20090612	IN 2008-DN10605	20081223		
KR 2009059105	A	20090610	KR 2009-701318	20090121			
PRIORITY APPLN. INFO.:			FR 2006-5540	A	20060621		
OTHER SOURCE(S):	MARPAT	148:100384	WO 2007-EP56225	W	20070621		
GI							



AB Title compds. I [X1 = halo, R1, G1R1; X2 = halo, R2, G2R2; X3 = R3, G3R3; X4 = halo, R4, G4R4; X5 = R5, G5R5; R1 = haloalkyl; R2 = H, alkyl; R3-R5 = independently H, (un)substituted alkyl; G1-G5 = independently O, S; with at least one of X3-X5 = R3, G3R3, R4, G4R4, R5, G5R5 in which G3-G5 = defined as above and R3-R5 = independently alkyl substituted with 1-2 substituents selected from CO2H and derivs., CONH2 and derivs., SO3H, SO2NH2 and derivs.; A = CR6R7, CO, C:N-OH, C:N-OR8; R6 = H, alkyl, OR8; R7 = alkyl, OH, OR8; R8 = independently alkyl substituted with an aryl or cycloalkyl group; D = CH2, CHY; Y = O- or S-heterocycle; and their stereoisomers, racemates, geometrical isomers, tautomers, salts, hydrates, solvates, solid forms and their mixts.] were prepared as PPAR activators, especially agonists, for treating dyslipidemia, diabetes type II and related diseases. Thus, reduction of 2-[2,6-dimethyl-4-[3-[4-(trifluoromethylthio)phenyl]-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid with triethylsilane in DCM in the presence of TFA at room temperature gave the acid II (m.p. = 83-85°). Selected I were hPPAR α ,

hPPARY, and/or hPPA8 activators in an induced luciferase activity via hPPAR α /Gal4, hPPAR γ /Gal4, and hPPAR δ /Gal4 transactivation assay. I displayed hypolipemic properties by lowering the plasmatic cholesterol and triglycerides rates. I are useful for treating diabetes type II, dyslipidemia, pathologies associated with metabolic syndrome, cardiovascular diseases, etc.

IT 824932-97-0 1000336-54-8 1000336-56-0


1000336-59-3, 2-[2,6-Dimethyl-4-[3-[4-(trifluoromethyl)phenyl]-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid 1000336-67-3, tert-Butyl 2-[[4-[3-(4-hydroxyphenyl)-3-oxoprop-1-enyl]-2,6-dimethylphenyl]oxy]-2-methylpropanoate 1000336-69-5, tert-Butyl 2-[[4-[3-(2-fluoro-4-hydroxyphenyl)-3-oxoprop-1-enyl]-2,6-dimethylphenyl]oxy]-2-methylpropanoate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1,3-diphenylpropane derivs. as PPAR activators for treating diseases especially dyslipidemia)


RN 824932-97-0 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-bromophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 1000336-54-8 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 1000336-56-0 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethyl)thiophenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 1000336-59-3 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethyl)phenyl]-1-

propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 1000336-67-3 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1000336-69-5 CAPLUS

CN Propanoic acid, 2-[4-[3-(2-fluoro-4-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:151078 CAPLUS

DOCUMENT NUMBER: 1461:229042

TITLE: Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients and their preparation, and use in the treatment of diseases

INVENTOR(S): Delhomel, Jean Francois; Caumont-Bertrand, Karine

PATENT ASSIGNEE(S): Genfit, Fr.

SOURCE: U.S. Pat. Appl. Publ., 98pp., Cont.-in-part of U.S. Ser. No. 520,079.

CODEN: USXXCO

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070032543	A1	20070208	US 2006-493040	20060726
FR 2841900	A1	20040109	FR 2002-8571	20020708
FR 2841900	B1	20070302		
WO 2004005233	A1	20040115	WO 2003-FR2127	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050176808	A1	20050811	US 2005-520079	20050422
PRIORITY APPLN. INFO.:			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
			US 2005-520079	A2 20050422

OTHER SOURCE(S): MARPAT 146:229042
GI



AB The invention concerns substituted 1,3-diphenylprop-2-en-1-one derivs. of formula I and combinations of said derivs. with other therapeutically active ingredients. The invention also concerns compns. comprising said derivs. or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathol. related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing. Compds. of formula I wherein X1 is H, halo, (un)substituted alkyl, OH and derivs., SH and derivs.; X3 is H, thionitroso, OH,

alkylcarbonyloxy, alkylxy, thio, alkylthio, alkylcarbonylthio, or O and S to form benzopyran derivative or benzothiopyran derivative; X3 - X5 are independently OH and derivs., SH and derivs., H, and (un)substituted alkyl; X6 is O, NH, and NOH and derivs.; and their optical and geometric isomers, racemates, tautomers, salts, hydrates, and mixts. thereof, are claimed. Example compound II was prepared by condensation of 4-[(ethoxycarbonyl)dimethylmethoxy]acetophenone with 3,5-di-*tert*-butyl-4-hydroxybenzaldehyde. All the invention compds. were evaluated for their antioxidant properties, PPAR activation, antiinflammatory activity, neuroprotective effect, lipid metabolism effect, and antidiabetic activity.


IT 923978-13-6P 923978-26-1P 923978-31-8P
 923978-35-2P 923978-37-4P 923978-39-6P
 923978-50-1P 923978-52-3P 923978-54-5P
 923978-56-7P 923978-60-3P 923978-62-5P
 923978-64-7P 923978-66-9P 923978-68-1P
 923978-70-5P 923978-72-7P 923978-74-9P
 923978-76-1P 923978-78-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of substituted diphenylpropenone derivs. and their use in combinations with other therapeutically active ingredients useful in treatment of diseases)

RN 923978-13-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-26-1 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-31-8 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexyloxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-35-2 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-(4-chloro-2-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-37-4 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-(4-heptylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 923978-39-6 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-(4-bromophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-50-1 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylsulfonyl)phenyl]phenoxy]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-52-3 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-[(trifluoromethyl)thiophenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-54-5 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(1-methylethyl)phenyl]phenoxy]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-56-7 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-60-3 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-(trifluoromethoxy)phenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 923978-62-5 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-(4-iodophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-64-7 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-fluorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-66-9 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-(4-nonyloxy)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-68-1 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(4-propoxypyphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-70-5 CAPLUS
CN Acetic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propenyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-72-7 CAPLUS
CN Acetic acid, 2-[2,6-bis(1-methylethyl)-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propenyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-74-9 CAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(octadecyloxy)phenyl]-3-oxo-1-propen-1-yl]phenoxyl-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 923978-76-1 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[4-(dodecyloxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxyl]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-78-3 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



IT 639864-34-9P 639864-35-0P 923978-04-5P

923978-12-5P 923978-15-8P 923978-23-8P

923978-25-0P 923978-27-2P 923978-32-9P

923978-36-3P 923978-38-5P 923978-40-9P

923978-51-2P 923978-53-4P 923978-55-6P

923978-57-8P 923978-61-4P 923978-63-6P

923978-65-8P 923978-67-0P 923978-69-2P

923978-71-6P 923978-73-8P 923978-75-0P

923978-77-2P 923978-79-4P 923978-82-9P


923978-83-0P 923978-94-3P 923978-95-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted diphenylpropanone derivs. and their use in combinations with other therapeutically active ingredients useful in treatment of diseases)

RN 639864-34-9 CAPLUS


CN Propanoic acid, 2-[4-[(3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl)-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 639864-35-0 CAPLUS

CN Propanoic acid, 2-[4-[(3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl)-2,6-dimethylphenoxy]-2-methyl-1,1-dimethylethyl ester (CA INDEX NAME)


2,6-dimethylphenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 923978-04-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-12-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-15-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-23-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-bromo-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-25-0 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-27-2 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-32-9 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexyloxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-36-3 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-chloro-2-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-38-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-heptylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-40-9 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-(4-bromophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-51-2 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylsulfonyl)phenyl]3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-53-4 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-[(trifluoromethyl)thio]phenyl]1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 923978-55-6 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(1-methylethyl)phenyl]3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-57-8 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-(trifluoromethyl)phenyl]propenyl]phenoxyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-61-4 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-(trifluoromethoxy)phenyl]propenyl]phenoxyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-63-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-iodophenyl)-3-oxo-1-propenyl]phenoxyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-65-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-fluorophenyl)-3-oxo-1-propenyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-67-0 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(nonyloxy)phenyl]-3-oxo-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-69-2 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(4-propoxyphe- nyl)-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-71-6 CAPLUS

CN Acetic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-73-8 CAPLUS

CN Acetic acid, 2-[2,6-bis(1-methylethyl)-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-75-0 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(octadecyloxy)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 923978-77-2 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-[4-(dodecyloxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-79-4 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-82-9 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexylthio)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-83-0 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexylthio)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 923978-94-3 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 923978-95-4 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-(2-bromoethoxy)phenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:729631 CAPLUS

DOCUMENT NUMBER: 143:193809

TITLE: Preparation of 1,3-diphenyl-2-propen-1-one as PPAR activators, particularly agonists, and antioxidants and their pharmaceutical and cosmetic compositions

INVENTOR(S): Caumont-Bertrand, Karine; Delhomel, Jean-Francois

PATENT ASSIGNEE(S): Genfit, Fr.

SOURCE: PCT Int. Appl., 153 pp.

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073184	A1	20050811	WO 2005-FR40	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW, BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2864956	A1	20050715	FR 2004-123	20040108
FR 2864956	B1	20060428		

AU 2005209446	A1	20050811	AU 2005-209446	20050107
CA 2550576	A1	20050811	CA 2005-2550576	20050107
EP 1701938	A1	20060920	EP 2005-717386	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1930122	A	20070314	CN 2005-80007226	20050107
BR 2005006718	A	20070502	BR 2005-6718	20050107
JP 2007517841	T	20070705	JP 2006-548344	20050107
NO 2006002824	A	20061005	NO 2006-2824	20060616
IN 2006DN03732	A	20070420	IN 2006-DN3732	20060629
US 20080058412	A1	20080306	US 2006-585329	20060706
US 7547729	B2	20090616		
MX 2006007867	A	20060926	MX 2006-7867	20060707
KR 2006132903	A	20061222	KR 2006-715988	20060808
PRIORITY APPLN. INFO.:				
			FR 2004-123	A 20040108
			FR 2004-9257	A 20040901
			WO 2005-FR40	W 20050107

OTHER SOURCE(S): MARPAT 143:193809
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X7 = (un)substituted O-alkyl, S-alkyl; X1-X5 = independently halo, thionitroso, alkoxy, aryloxy, S-alkyl, etc.; X6, X8 = independently H, halo, alkoxy, etc.; with provisos; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptor agonists and antioxidants. Ten biol. examples are given. For example, (E)-II (m.p. = 177-179°) was prepared via condensation of 3,5-dimethyl-4-methylthioacetophenone (preparation given) with 3,5-dimethyl-4-hydroxybenzaldehyde, followed by O-alkylation of phenol with tert-Bu bromoisobutyrate and acidolysis of the ester. (E)-III displayed antioxidant properties as demonstrated by diminution of the production of conjugated dienes after Cu-induced LDL oxidation by 90%. (E)-II showed induced luciferase activity via PPAR α /Gal4 transactivation with an induction factor of 17.05 at 1 μ M. I are useful for treating cardiovascular diseases, dyslipidemia, syndrome X, diabetes, obesity, hypertension, inflammations, dermatol. diseases, cerebral ischemia and the disorders related to the oxidative stress, for treating aging, in particular cutaneous aging.


IT 858420-74-3P, (E)-1-[4-[(2-(Fentylthio)ethyl)oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-76-5P, (E)-1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-78-7P, (E)-1-[4-[(1,2)Dithiolan-3-yl]pentyl]oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-07-8P, (E)-1-[4-[(2-Cyclohexylethyl)oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-09-0P, (E)-1-(4-Methylthio-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-11-4P, (E)-1-(4-Propyloxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-13-6P, (E)-1-(4-Methoxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-15-8P, (E)-1-(4-Hexyloxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-17-0P, (E)-1-[4-(2-Cyclohexylethyl)oxy]-3,5-

dimethylphenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-19-2P,
 (E)-1-[4-[[2-(Cyclohexylthio)ethyl]oxy]phenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-21-6P, (E)-1-[2,4,5-Trimethylphenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-23-8P, (E)-1-[4-[[2-(Cyclohexylthio)ethyl]oxy]-3,5-dimethylphenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-27-2P,
 (E)-1-(2,3,4,5,6-Pentamethylphenyl)-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-29-4P, (E)-1-(4-Phenoxyloxyphenyl)-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-31-8P, (E)-1-(4-Methoxy-3-fluorophenyl)-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-33-0P, (E)-1-(4-Methoxy-3-methylphenyl)-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-35-2P, (E)-1-[4-(Hexylthio)-3,5-dimethylphenyl]-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-39-6P, (E)-1-[3,5-Dimethyl-4-[[2-(morpholin-4-yl)ethyl]oxy]phenyl]-3-[4-[[[(ethoxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one hydrochloride 862099-43-2P,
 (E)-1-(4-Methoxy-3-trifluoromethylphenyl)-3-[4-[[[(tert-butyloxy)carbonyl]dimethylmethoxy]oxy]-3,5-dimethylphenyl]prop-2-en-1-one
 RL: COS (Cosmetic use); PAC (Pharmacological activity); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 1,3-di-Ph-2-propen-1-one as PPAR agonists and antioxidants and their pharmaceutical and cosmetic compns.)

RN 858420-74-3 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-[2-(pentylthio)ethoxy]phenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-76-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-78-7 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-07-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-[(2-cyclohexylethoxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-09-0 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[3,5-dimethyl-4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-11-4 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(3,5-dimethyl-4-propoxypyhenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-13-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethyl ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-15-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexyloxy)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-17-0 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(2-cyclohexylethoxy)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 862099-19-2 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(2-(cyclohexylthio)ethoxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 862099-21-6 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(2,4,5-trimethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester
(CA INDEX NAME)


Double bond geometry as shown.



RN 862099-23-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-[2-(cyclohexylthio)ethoxy]-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-27-2 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(2,3,4,5,6-pentamethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-29-4 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(4-phenoxyphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-31-8 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-(3-fluoro-4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-33-0 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxy-3-methylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 862099-35-2 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexylthio)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-39-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.




• HCl

RN 862099-43-2 CAPLUS

CN Propanoic acid, 2-[4-((1E)-3-[4-methoxy-3-(trifluoromethyl)phenyl]-3-oxo-1-propen-1-yl)-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



IT 858420-75-4P, (E)-1-[4-[(2-(Pentylthio)ethyl]oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
 858420-77-6P, (E)-1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
 858420-79-8P, (E)-1-[4-[5-((1,2)Dithiolan-3-yl)pentyl]oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
 858420-83-4P, 1-[4-[(2-(Pentylthio)ethyl]oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
 858420-84-5P, 1-[4-[(2-(Cyclohexylthio)ethyl]oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one

858420-86-7P, 1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-87-8P, 1-(4-Methoxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-88-9P, 1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3-[4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one
858420-89-0P, 1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-91-4P, 1-(4-Mercapto-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-92-5P, 1-(4-Methylthio-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-93-6P, 1-[4-[(2-Cyclohexylethyl)thio]-3,5-dimethylphenyl]prop-2-en-1-one
858420-94-7P, 1-(4-Hexylthio-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-95-8P, 1-(2,5-Dihydroxy-3,4,6-trimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-96-9P, 1-(2,5-Dimethoxy-3,4,6-trimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858420-99-2P, 1-[4-[(2-Phenylethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
858421-00-8P, 1-[4-[(2-(Morpholin-4-yl)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862098-83-7P, 1-[3,5-Dimethyl-4-[(2-(morpholin-4-yl)ethyl)oxy]phenyl]-3-[4-[(ethoxy)carbonyl]dimethylmethyl]oxy]-3,5-dimethylphenyl]prop-2-en-1-one hydrochloride 862098-91-7P,
1-[3,5-Dimethyl-4-[(2-(morpholin-4-yl)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-08-9P, (E)-1-[4-[(2-Cyclohexylethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-10-3P, (E)-1-(4-Methylthio-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-12-5P, (E)-1-(4-Propyloxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-14-7P, (E)-1-(4-Methoxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-16-9P, (E)-1-(4-Hexyloxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-18-1P, (E)-1-[4-[(2-Cyclohexylethyl)oxy]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-20-5P,
(E)-1-[4-[(2-(Cyclohexylthio)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-22-7P, (E)-1-(2,4,5-Trimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-24-9P, (E)-1-[4-[(2-(Cyclohexylthio)ethyl)oxy]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-28-3P, (E)-1-(2,3,4,5,6-Pentamethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-30-7P,
(E)-1-(4-Phenoxyphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-32-9P,
(E)-1-(4-Methoxy-3-fluorophenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-34-1P,
(E)-1-(4-Methoxy-3-methylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-36-3P,
(E)-1-[4-(Hexylthio)-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 862099-40-9P,
(E)-1-[3,5-Dimethyl-4-[(2-(morpholin-4-yl)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one

862099-44-3P, (E)-1-[4-Methoxy-3-(trifluoromethyl)phenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-47-6P, 1-[4-[(2-(Pentylthio)ethyl)oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-49-8P, 1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-51-2P, 1-[4-[(5-((1,2-Dithiolan-3-yl)pentyl)oxy)phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-54-5P, 1-[4-[(2-Cyclohexylethyl)oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-55-6P, 1-[4-[(2-Cyclohexylethyl)oxy]phenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-59-0P, 1-(4-Propyloxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-60-3P, 1-(4-Propyloxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-61-4P, 1-(4-Methoxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-62-5P, 1-(4-Hexyloxy-3,5-dimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-63-6P, 1-(4-Hexyloxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-64-7P, 1-[4-[(2-Cyclohexylethyl)oxy]-3,5-dimethylphenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-65-8P, 1-[4-[(2-Cyclohexylethyl)oxy]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-66-9P, 1-[4-[(2-Cyclohexylethio)ethyl]oxy]-3,5-dimethylphenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-67-0P, 1-(2,4,5-Trimethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-68-1P, 1-(2,4,5-Trimethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-69-2P, 1-[4-[(2-Cyclohexylethio)ethyl]oxy]-3,5-dimethylphenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-70-5P, 1-[4-[(2-Cyclohexylethio)ethyl]oxy]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-73-8P, 1-(2,3,4,5,6-Pentamethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-74-9P, 1-(2,3,4,5,6-Pentamethylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-75-0P, 1-(4-Phenoxyphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-76-1P, 1-(4-Phenoxyphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-77-2P, 1-(4-Methoxy-3-fluorophenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-78-3P, 1-(4-Methoxy-3-fluorophenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-79-4P, 1-(4-Methoxy-3-methylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-80-7P, 1-(4-Methoxy-3-methylphenyl)-3-[4-[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-81-8P, 1-[4-(Hexylthio)-3,5-dimethylphenyl]-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-85-2P, 1-(4-Methoxy-3-trifluoromethylphenyl)-3-[4-[(tert-butyloxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one
862099-86-3P, 1-(4-Methoxy-3-trifluoromethylphenyl)-3-[4-


[(carboxydimethylmethyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,3-di-Ph-2-propen-1-one as PPAR agonists and antioxidants and their pharmaceutical and cosmetic compns.)

RN 858420-75-4 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-[2-(pentylthio)ethoxy]phenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-77-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-79-8 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 858420-83-4 CAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[(3-oxo-3-[4-[2-(pentylthio)ethoxy]phenyl]-1-propen-1-yl)phenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-84-5 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-[(2-methylpropenyl)oxy]phenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-86-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-hydroxy-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 858420-87-8 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-methoxy-3,5-dimethylphenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-88-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-[(1,2-dithiolan-3-yl)pentyl]oxy]-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-89-0 CAPLUS

CN Propanoic acid, 2-[4-[3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-91-4 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-mercaptoproxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-92-5 CAPLUS

CN Propanoic acid, 2-[4-[3-[3,5-dimethyl-4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-93-6 CAPLUS


CN Propanoic acid, 2-[4-[3-[4-[(2-cyclohexylethyl)thio]-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-94-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(hexylthio)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-95-8 CAPLUS
 CN Propanoic acid, 2-[4-[3-(2,5-dihydroxy-3,4,6-trimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-96-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-(2,5-dimethoxy-3,4,6-trimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-99-2 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-(2-phenylethoxy)phenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 858421-00-8 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 862098-83-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862098-91-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 862099-08-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(2-cyclohexylethoxy)phenyl]-3-oxo-1-propen-

1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-10-3 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[3,5-dimethyl-4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-12-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(3,5-dimethyl-4-propoxophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-14-7 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-16-9 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexyloxy)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-18-1 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-(2-cyclohexylethoxy)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-20-5 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-[4-[2-(cyclohexylthio)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-22-7 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(2,4,5-trimethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-24-9 CAPLUS
 CN Propanoic acid, 2-[4-[(1E)-3-[4-[2-(cyclohexylthio)ethoxy]-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 862099-28-3 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(2,3,4,5,6-pentamethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-30-7 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-(4-phenoxyphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-32-9 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(3-fluoro-4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 862099-34-1 CAPLUS


CN Propanoic acid, 2-[4-[(1E)-3-(4-methoxy-3-methylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-36-3 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[4-(hexylthio)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-40-9 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 862099-44-3 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[4-methoxy-3-(trifluoromethyl)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 862099-47-6 CAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-[2-(pentylthio)ethoxy]phenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OBu-t


RN 862099-49-8 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-51-2 CAPLUS

CN Propanoic acid, 2-[4-[3-[4-[[5-(1,2-dithiolan-3-yl)pentyl]oxylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-54-5 CAPLUS


CN Propanoic acid, 2-[4-[3-[4-(2-cyclohexylethoxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-55-6 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(2-cyclohexylethoxy)phenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-58-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-[3,5-dimethyl-4-(methylthio)phenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-59-0 CAPLUS
 CN Propanoic acid, 2-[4-[3-(3,5-dimethyl-4-propoxypyphenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-60-3 CAPLUS
 CN Propanoic acid, 2-[4-[3-(3,5-dimethyl-4-propoxypyphenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-61-4 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-methoxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-62-5 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-(hexyloxy)-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-63-6 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-(hexyloxy)-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-64-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-(2-cyclohexylethoxy)-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-65-8 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(2-cyclohexylethoxy)-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-66-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(2-(cyclohexylthio)ethoxy)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-67-0 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(2,4,5-trimethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-68-1 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(2,4,5-trimethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-69-2 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-[2-(cyclohexylthio)ethoxy]-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-70-5 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-[2-(cyclohexylthio)ethoxy]-3,5-dimethylphenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 862099-73-8 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(2,3,4,5,6-pentamethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-74-9 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(2,3,4,5,6-pentamethylphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-75-0 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(4-phenoxyphenyl)-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-76-1 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-(4-phenoxyphenyl)-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-77-2 CAPLUS

CN Propanoic acid, 2-[4-[3-(3-fluoro-4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-78-3 CAPLUS

CN Propanoic acid, 2-[4-[3-(3-fluoro-4-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-79-4 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-methoxy-3-methylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-80-7 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-methoxy-3-methylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 862099-81-8 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-(hexylthio)-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862099-85-2 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-methoxy-3-(trifluoromethyl)phenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 862099-86-3 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-methoxy-3-(trifluoromethyl)phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:610755 CAPLUS
 DOCUMENT NUMBER: 143:133180
 TITLE: Compound derived from 1,3-diphenyl-2-propen-1-one, preparation, and use as PPAR, in particular PPAR α , agonists and antioxidants
 INVENTOR(S): Caumont, Bertrand Karine; Delhomel, Jean Francois
 Genfit S.A., Fr.
 SOURCE: Fr. Demande, 67 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2864956	A1	20050715	FR 2004-123	20040108
FR 2864956	B1	20060428		
AU 2005209446	A1	20050811	AU 2005-209446	20050107
CA 2550576	A1	20050811	CA 2005-2550576	20050107
WO 2005073184	A1	20050811	WO 2005-FR40	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1701938	A1	20060920	EP 2005-717386	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1930122	A	20070314	CN 2005-80007226	20050107
BR 2005006718	A	20070502	BR 2005-6718	20050107
JP 2007517841	T	20070705	JP 2006-548344	20050107
NO 2006002824	A	20061005	NO 2006-2824	20060616
IN 2006DN03732	A	20070420	IN 2006-DN3732	20060629
US 20080058412	A1	20080306	US 2006-585329	20060706
US 75477729	B2	20090616		
MX 2006007867	A	20060926	MX 2006-7867	20060707
ZA 2006006542	A	20080730	ZA 2006-6542	20060807
KR 2006132903	A	20061222	KR 2006-715988	20060808
PRIORITY APPLN. INFO.:				
				FR 2004-123
				FR 2004-9257
				WO 2005-FR40
				A 20040108
				A 20040901
				W 20050107

OTHER SOURCE(S): MARPAT 143:133180
GI



AB Title compds. I [$X^7 =$ (un)substituted O-alkyl, S-alkyl; $X1-X5 =$ independently halo, thionitroso, alkoxy, aryloxy, etc.; $X6, X8 =$ independently halo, H, alkoxy, etc; with provisos; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptor- α (PPAR α) agonists and antioxidants. Eight biol. examples are given. For example, II was prepared by condensation of 4-[(2-(pentylthio)ethyl)oxy]acetophenone (preparation given) with 4-hydroxy-3,5-dimethylbenzaldehyde, O-alkylation with tert-Bu 2-bromoisobutyrate and ester acidolysis. II displayed antioxidant properties as demonstrated by reduction of 90% in the in vitro production of conjugated dienes after Cu-induced LDL oxidation. II showed induced luciferase activity via PPAR α /Gal4 transactivation with an induction factor of 18.49 at 10 μ M. I are useful for treating cardiovascular diseases, dyslipidemia, syndrome X, diabetes, obesity, hypertension, inflammations, dermatol. diseases, cerebral ischemia and the disorders

related to the oxidative stress, for treating aging, in particular cutaneous aging.

IT 858420-74-3P, (E)-1-[4-[(2-(Pentylthio)ethyl)oxy]phenyl]-3-[4-[(tert-butoxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-75-4P, (E)-1-[4-[(2-(Pentylthio)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-76-5P, (E)-1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(tert-butoxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-77-6P, (E)-1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-78-7P, (E)-1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]phenyl]-3-[4-[(tert-butoxy)carbonyl]dimethylmethoxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-79-8P, (E)-1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-82-3P, (E)-1-(4-Bromophenyl)-3-[3,5-dimethyl-4-[(ethoxy)carbonyl](phenyl)methoxy]phenyl]prop-2-en-1-one 858420-83-4P, 1-[4-[(2-(Pentylthio)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-84-5P, 1-[4-[(2-(Cyclohexylthio)ethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-86-7P, 1-(4-Hydroxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-87-8P, 1-(4-Methoxy-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-88-9P, 1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-89-0P, 1-[4-[(5-((1,2)Dithiolan-3-yl)pentyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-90-3P, 1-(4-Bromophenyl)-3-[4-[(carboxy)(phenyl)methoxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-91-4P, 1-(4-Mercapto-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-92-5P, 1-(4-Methylthio-3,5-dimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-93-6P, 1-[4-[(2-Cyclohexylethyl)thio]-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-94-7P, 1-[4-(Hexylthio)-3,5-dimethylphenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-95-8P, 1-(2,5-Dihydroxy-3,4,6-trimethylphenyl)-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858420-96-9P 858420-99-2P,

1-[4-[(2-Phenylethyl)oxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one 858421-00-8P, 1-[4-[(2-Morpholin-4-yl)ethoxy]phenyl]-3-[4-[(carboxydimethylmethoxy)oxy]-3,5-dimethylphenyl]prop-2-en-1-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,3-di-Ph-2-propen-1-one as PPAR, in particular PPAR α , agonists and antioxidants and their pharmaceutical and cosmetic compns.)

RN 858420-74-3 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-1-4-[(1E)-3-oxo-3-[4-[(pentylthio)ethoxy]phenyl]-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-75-4 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-oxo-3-[4-[2-(pentylthio)ethoxy]phenoxy]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-76-5 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-77-6 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-78-7 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-79-8 CAPLUS

CN Propanoic acid, 2-[4-[(1E)-3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 858420-82-3 CAPLUS


CN Benzeneacetic acid, α -[(1E)-3-(4-bromophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 858420-83-4 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-[2-(pentylthio)ethoxy]phenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-84-5 CAPLUS

CN Propanoic acid, 2-[4-[3-[4-[2-(cyclohexylthio)ethoxy]phenyl]-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-86-7 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-hydroxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-87-8 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-methoxy-3,5-dimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-88-9 CAPLUS

CN Propanoic acid, 2-[4-[3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-89-0 CAPLUS

CN Propanoic acid, 2-[4-[3-[4-[(5-(1,2-dithiolan-3-yl)pentyl)oxy]phenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-90-3 CAPLUS

CN Benzeneacetic acid, α -[4-[3-(4-bromophenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]- (CA INDEX NAME)




RN 858420-91-4 CAPLUS


CN Propanoic acid, 2-[4-[3-(4-mercaptopro-3,5-dimethylphenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-92-5 CAPLUS
 CN Propanoic acid, 2-[4-[3-(3,5-dimethyl-4-(methylthio)phenyl)-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-93-6 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-[(2-cyclohexylethyl)thio]-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 858420-94-7 CAPLUS
 CN Propanoic acid, 2-[4-[3-[4-(hexylthio)-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-95-8 CAPLUS
 CN Propanoic acid, 2-[4-[3-[2,5-dihydroxy-3,4,6-trimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-96-9 CAPLUS

CN Propanoic acid, 2-[4-[3-(2,5-dimethoxy-3,4,6-trimethylphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 858420-99-2 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-oxo-3-[4-(2-phenylethoxy)phenyl]-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 858421-00-8 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:33165 CAPLUS

DOCUMENT NUMBER: 142:134317

TITLE: Preparation of carboxyalkyloxy- and

carboxyalkylthio-1,3-diphenylprop-2-en-1-one
 derivatives via O- and S-alkylation
 INVENTOR(S): Delhomel, Jean Francois; Caumont, Bertrand Karine
 PATENT ASSIGNEE(S): Genfit S.A., Fr.
 SOURCE: Fr. Demande, 40 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2857361	A1	20050114	FR 2003-8354	20030708
FR 2857361	B1	20050909		
AU 2004255905	A1	20050120	AU 2004-255905	20040708
CA 2531443	A1	20050120	CA 2004-2531443	20040708
WO 2005005369	A1	20050120	WO 2004-FR1797	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1644312	A1	20060412	EP 2004-767629	20040708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1819986	A	20060816	CN 2004-80019564	20040708
BR 2004012370	A	20060905	BR 2004-12370	20040708
SG 129448	A1	20070226	SG 2007-644	20040708
JP 2007516189	T	20070621	JP 2006-518300	20040708
NZ 544792	A	20090228	NZ 2004-544792	20040708
IN 2006DN00051	A	20070824	IN 2006-DN51	20060103
MX 2006000159	A	20060321	MX 2006-159	20060105
NO 2006000087	A	20060207	NO 2006-87	20060106
KR 2006030110	A	20060407	KR 2006-700562	20060109
US 20060142611	A1	20060629	US 2006-563057	20060202
US 7385082	B2	20080610		
ZA 2006001040	A	20070530	ZA 2006-1040	20060206
PRIORITY APPLN. INFO.:			FR 2003-8314	A 20030708
			WO 2004-FR1797	W 20040708
OTHER SOURCE(S):	CASREACT 142:134317; MARPAT 142:134317			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is directed to a method of preparation of 1,3-diphenylprop-2-en-1-one of formula I and II, substituted on one of the two Ph groups with a carboxyalkylthio or a carboxyalkyloxy, by O- or S-alkylation of the corresponding thio/phenols with halocarboxylates YR, and Thio-*acidolysis* of the resulting ester |X1 = halo, R1, G1R1; X2 = H, thionitroso, alkylxyloxy, alkylcarbonyloxy, alkylthio, alkylcarbonylthio; X3 = R3, G3R3, X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; R1, R3, R4, R5 = independently H, alkyl (un)substituted by a carboxylic acid group; G1,

G3, G4, G5 = independently O, S, with one of X1, X3, X4, or X5 being of formula GR, wherein G = defined as above, R = carboxyalkyl; Y = halo]. The advantage includes higher global yield of product. Thus, reacting II with tert-Bu 2-bromoisobutyrate in MeCN the presence of K2CO3 at reflux for 10 h, and TFA-acidolysis gave III in 56% global yield.


Claisen-Schmidt condensation of 4-chloroacetophenone with 3,5-dimethyl-4-hydroxybenzaldehyde in the presence of gaseous HCl saturated with EtOH gave II in 91%.

IT 824932-84-5P, 1-(4-Chlorophenyl)-3-[3,5-dimethyl-4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]phenyl]prop-2-en-1-one
 824932-90-3P, 1-(4-Methylthiophenyl)-3-[3,5-dimethyl-4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]phenyl]prop-2-en-1-one
 824932-93-6P, 1-(4-Hexyloxyphenyl)-3-[3,5-dimethyl-4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]phenyl]prop-2-en-1-one
 824932-99-9P, 1-(2-Methyloxy-4-chlorophenyl)-3-[3,5-dimethyl-4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]phenyl]prop-2-en-1-one
 824932-99-2P, 1-(4-Bromophenyl)-3-[3,5-dimethyl-4-[(tert-butyloxy)carbonyl]dimethylmethyl]oxy]phenyl]prop-2-en-1-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carboxyalkylthio- and carboxyalkyloxy-1,3-diphenylprop-2-en-1-one derivs. by O- or S-alkylation of thio/phenols and acidolysis)


RN 824932-84-5 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 824932-90-3 CAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 824932-93-6 CAPLUS


CN Propanoic acid, 2-[4-[3-(4-(hexyloxy)phenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 824932-96-9 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-chloro-2-methoxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 824932-99-2 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-bromophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 824932-82-3P, 1-(4-Chlorophenyl)-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one 824932-88-9P,
 1-(4-Methylthiophenyl)-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one 824932-91-4P,
 1-(4-Hexyloxyphenyl)-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one 824932-94-7P,
 1-(2-Methyoxy-4-chlorophenyl)-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one 824932-97-0P,
 1-(4-Bromophenyl)-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(product; preparation of carboxyalkylthio- and carboxyalkyloxy-1,3-diphenylprop-2-en-1-one derivs. by O- or S-alkylation of thio/phenols and acidolysis)


RN 824932-82-3 CAPLUS
 CN Propanoic acid, 2-[4-[3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)




RN 824932-88-9 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 824932-91-4 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(hexyloxy)phenyl]-3-oxo-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 824932-94-7 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-(4-chloro-2-methoxyphenyl)-3-oxo-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 824932-97-0 CAPLUS
 CN Propanoic acid, 2-[2,6-dimethyl-4-[3-(4-bromophenyl)-3-oxo-1-propenyl]phenoxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:19768 CAPLUS

DOCUMENT NUMBER: 140:76897

TITLE: Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as antioxidants for treating cerebral ischemia and related diseases

INVENTOR(S): Najib, Jamila; Caumont Bertrand, Karine

PATENT ASSIGNEE(S): Genfit S.A., Fr.

SOURCE: Fr. Demande, 66 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2841900	A1	20040109	FR 2002-8571	20020708
FR 2841900	B1	20070302		
CA 2490986	A1	20040115	CA 2003-2490986	20030708
WO 2004005233	A1	20040115	WO 2003-FR2127	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG				
AU 2003264698	A1	20040123	AU 2003-264698	20030708
BR 2003012398	A	20050412	BR 2003-12398	20030708
EP 1525177	A1	20050427	EP 2003-762749	20030708
EP 1525177	B1	20070627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668565	A	20050914	CN 2003-816366	20030708
JP 2005532385	T	20051027	JP 2004-518890	20030708
AT 365703	T	20070715	AT 2003-762749	20030708
NZ 538051	A	20071130	NZ 2003-538051	20030708
ES 2287528	T3	20071216	ES 2003-762749	20030708
NO 2004005301	A	20050204	NO 2004-5301	20041203
MX 2005000427	A	20050930	MX 2005-427	20050107
ZA 2005001082	A	20070131	ZA 2005-1082	20050207
US 20050176808	A1	20050811	US 2005-520079	20050422
US 20070032543	A1	20070208	US 2006-493040	20060726
PRIORITY APPLN. INFO.:			FR 2002-8571	A 20020708

OTHER SOURCE(S):
GI

MAPAT 140:76897

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkylxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors- α (PPAR α) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I diminished the formation of oxidation product of LDL by 33%. Selected I were PPAR α agonists and showed induced luciferase activity via PPAR α /Gal4 transactivation. I are neuroprotectants useful for treating ischemia.

IT 639864-34-9P, 1-(2-Hydroxy-4-chlorophenyl)-3-(3,5-dimethyl-4-carboxymethylmethoxyphenyl)prop-2-en-1-one 639864-35-0P,
1-(2-Hydroxy-4-chlorophenyl)-3-[3,5-dimethyl-4-[(isopropoxy)carbonyl]dimethylmethyl]oxy]phenylprop-2-en-1-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR α agonist; preparation of diphenylpropenones as PPAR agonists for treating ischemia)

RN 639864-34-9 CAPLUS


CN Propanoic acid, 2-[4-[3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



C1

RN 639864-35-0 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:19750 CAPLUS
 DOCUMENT NUMBER: 140:76896
 TITLE: Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPAR α agonists, antioxidants as well as antiinflammatory agents
 INVENTOR(S): Najib, Jamila; Caumont Bertrand, Karine
 PATENT ASSIGNEE(S): Genfit S.A., Fr.
 SOURCE: Fr. Demande, 66 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2841784	A1	20040109	FR 2002-8570	20020708
FR 2841784	B1	20070302		
CA 2490993	A1	20040115	CA 2003-2490993	20030708
WO 2004005243	A2	20040115	WO 2003-FR2128	20030708
WO 2004005243	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264699	A1	20040123	AU 2003-264699	20030708
EP 1519908	A2	20050406	EP 2003-762750	20030708
EP 1519908	B1	20070613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012399	A	20050412	BR 2003-12399	20030708
CN 1688532	A	20051026	CN 2003-816351	20030708
JP 2005532386	T	20051027	JP 2004-518891	20030708
AT 364588	T	20070715	AT 2003-762750	20030708
NZ 538052	A	20070928	NZ 2003-538052	20030708
ES 2287529	T3	20071216	ES 2003-762750	20030708
NO 2004005082	A	20041227	NO 2004-5082	20041122
MX 2005000425	A	20050722	MX 2005-425	20050107
ZA 2005001081	A	20070425	ZA 2005-1081	20050207
US 20050171149	A1	20050804	US 2005-520078	20050404

PRIORITY APPLN. INFO.:

FR 2002-8570
WO 2003-FR2128A 20020708
W 20030708

OTHER SOURCE(S):

MARPAT 140:76896

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkylxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors- α (PPAR α) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I (10-3 M) diminished the formation of oxidation product of LDL by 33%. Selected I were PPAR α agonists, showing induced luciferase activity via PPAR α /Gal4 transactivation with a factor of induction ranging from 10 to 60, 5-50 and 3-35 at 100 μ M, 30 μ M, and 10 μ M resp. I and their compns. are useful for treating cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative diseases, dermatol. and the disorders related to the oxidative stress, for preventing and treating aging, and in particular cutaneous aging.


IT 639864-34-9P 639864-35-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR α agonist; preparation of diphenylpropenones as PPAR agonists for treating ischemia)


RN 639864-34-9 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl- (CA INDEX NAME)



RN 639864-35-0 CAPLUS

CN Propanoic acid, 2-[4-[3-(4-chloro-2-hydroxyphenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
 ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
 LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	51.62	237.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.56	-6.56

STN INTERNATIONAL LOGOFF AT 15:25:50 ON 25 JUN 2009